Spero Therapeutics (SPRO) Competitors $0.75 +0.01 (+1.92%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.76 +0.01 (+0.77%) As of 04/17/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. ACTU, MOLN, RZLT, ACIU, TARA, DMAC, IKT, PBYI, TNGX, and DERMShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Actuate Therapeutics (ACTU), Molecular Partners (MOLN), Rezolute (RZLT), AC Immune (ACIU), Protara Therapeutics (TARA), DiaMedica Therapeutics (DMAC), Inhibikase Therapeutics (IKT), Puma Biotechnology (PBYI), Tango Therapeutics (TNGX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Actuate Therapeutics Molecular Partners Rezolute AC Immune Protara Therapeutics DiaMedica Therapeutics Inhibikase Therapeutics Puma Biotechnology Tango Therapeutics Journey Medical Actuate Therapeutics (NASDAQ:ACTU) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is ACTU or SPRO more profitable? Spero Therapeutics has a net margin of 3.30% compared to Actuate Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat Actuate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Spero Therapeutics 3.30%4.03%2.21% Do insiders & institutionals have more ownership in ACTU or SPRO? 25.6% of Spero Therapeutics shares are owned by institutional investors. 4.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to ACTU or SPRO? In the previous week, Actuate Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Actuate Therapeutics and 0 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.00 beat Actuate Therapeutics' score of -0.62 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Actuate Therapeutics Negative Spero Therapeutics Neutral Does the MarketBeat Community favor ACTU or SPRO? Spero Therapeutics received 208 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 69.67% of users gave Spero Therapeutics an outperform vote. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Which has better valuation & earnings, ACTU or SPRO? Spero Therapeutics has higher revenue and earnings than Actuate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ASpero Therapeutics$27.40M1.54$22.81M-$1.27-0.59 Do analysts prefer ACTU or SPRO? Actuate Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 150.00%. Spero Therapeutics has a consensus price target of $5.00, indicating a potential upside of 562.95%. Given Spero Therapeutics' higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummarySpero Therapeutics beats Actuate Therapeutics on 11 of the 14 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.16M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio10.786.8921.8017.78Price / Sales1.54231.03379.9697.74Price / Cash1.6265.6738.2634.64Price / Book0.375.916.443.97Net Income$22.81M$142.72M$3.21B$247.65M7 Day Performance25.70%4.38%2.85%1.80%1 Month Performance0.24%-12.76%-8.64%-6.98%1 Year Performance-48.69%-9.69%11.38%1.34% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.102 of 5 stars$0.75+1.9%$5.00+563.0%-49.7%$42.16M$27.40M10.78150ACTUActuate TherapeuticsN/A$8.00+4.4%$20.00+150.0%N/A$156.26MN/A0.0010News CoverageMOLNMolecular Partners1.6208 of 5 stars$3.86-0.3%$12.00+210.9%+1.5%$155.85M$4.97M-1.80180RZLTRezolute2.8953 of 5 stars$2.57+4.0%$24.38+848.4%-15.1%$155.58MN/A-2.1140Positive NewsGap UpACIUAC Immune2.5357 of 5 stars$1.52-2.6%$12.00+689.5%-38.8%$152.62M$27.31M-3.30140Analyst RevisionNews CoveragePositive NewsTARAProtara Therapeutics1.8158 of 5 stars$4.14+5.9%$22.50+443.5%+42.9%$152.22MN/A-1.4730Analyst ForecastNews CoveragePositive NewsGap UpDMACDiaMedica Therapeutics1.1009 of 5 stars$3.54+2.0%$8.00+126.0%+36.2%$151.71MN/A-6.3220Short Interest ↑News CoveragePositive NewsGap UpIKTInhibikase Therapeutics1.0421 of 5 stars$2.00-3.4%$6.50+225.0%-11.0%$148.68M$260,000.00-0.756PBYIPuma Biotechnology3.3403 of 5 stars$2.93+3.9%$7.00+138.9%-44.7%$145.36M$230.47M6.10200Analyst UpgradeTNGXTango Therapeutics2.0971 of 5 stars$1.34-5.0%$12.33+820.4%-82.7%$144.87M$42.07M-1.1490Analyst RevisionNews CoveragePositive NewsGap DownDERMJourney Medical2.2147 of 5 stars$6.21+3.0%$9.88+59.0%+61.9%$143.48M$56.13M-6.6190Short Interest ↑ Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Molecular Partners Alternatives Rezolute Alternatives AC Immune Alternatives Protara Therapeutics Alternatives DiaMedica Therapeutics Alternatives Inhibikase Therapeutics Alternatives Puma Biotechnology Alternatives Tango Therapeutics Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRO Stock Free SPRO Stock Alerts